Acromegaly
2008; Elsevier BV; Volume: 37; Issue: 1 Linguagem: Inglês
10.1016/j.ecl.2007.10.002
ISSN1558-4410
AutoresAnat Ben-Shlomo, Шломо Мелмед,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoAcromegaly is caused by growth hormone hypersecretion, mostly from a pituitary adenoma, driving insulin-like growth factor 1 overproduction. Manifestations include skeletal and soft tissue growth and deformities; and cardiac, respiratory, neuromuscular, endocrine, and metabolic complications. Increased morbidity and mortality require early and tight disease control. Surgery is the treatment of choice for microadenomas and well-defined intrasellar macroadenomas. Complete resection of large and invasive macroadenomas rarely is achieved; hence, their low rate of disease remission. Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control.
Referência(s)